Investment Rating - The industry investment rating is "Positive" [1] Core Viewpoints - The report indicates that the turning point has been reached, and there is optimism regarding the elasticity of the scientific services sector [3][6] - The sector has experienced significant adjustments in funding, and with the combination of fundamental turning points and policy support, a valuation reversal is expected [4] Summary by Sections 1. Funding Situation - As of Q1 2025, the total market value of institutional holdings in the scientific services sector is 3.286 billion, accounting for 0.11% of total fund holdings, indicating a low allocation by institutions [4][12] - From January 1, 2025, to May 7, 2025, the average increase in the scientific services sector was 9%, outperforming the pharmaceutical index by 7.7 percentage points [4][13] 2. Fundamentals - **Revenue**: The average year-on-year revenue growth for core scientific service targets in 2024 is 7.17%, with significant recovery in low-consumption categories [5][23] - **Gross Margin**: The average gross margin for core targets in 2024 is 47.99%, with a gradual recovery expected as cost control and capacity utilization improve [5][25] - **Capital Expenditure**: The total capital expenditure for the sector in 2024 is 4.643 billion, a decrease of 35% year-on-year, indicating a shift towards an investment harvest period [5][29] - **Inventory**: The average inventory turnover rate for core targets in 2024 is 3.7 times, showing an optimization trend [5][39] - **Net Profit Margin**: The average net profit margin for core targets in 2024 is 5.22%, with a slight increase to 5.47% in Q1 2025, indicating a recovery in profitability [5][50] 3. Investment Recommendations - The report recommends focusing on companies with strong growth certainty and clear trends in profitability improvement, highlighting Titan Technology, Haoyuan Pharmaceutical, Bid Medical, and Nanwei Technology as key recommendations [7][53]

南京诺唯赞生物科技股份有限公司 2024 年年度股东会 会议资料 2025 年 5 月 南京诺唯赞生物科技股份有限公司 2024 年年度股东会会议资料 南京诺唯赞生物科技股份有限公司 2024 年年度股东会会议须知 为维护全体股东合法权益，确保股东会的正常秩序和议事效率，保证股东会 的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、中 国证券监督管理委员会《上市公司股东会规则》以及《南京诺唯赞生物科技股份 有限公司章程》、《南京诺唯赞生物科技股份有限公司股东大会议事规则》等有 关规定，南京诺唯赞生物科技股份有限公司（以下简称"公司"）特制定本次股 东会会议须知： 一、董事会在股东会召开过程中，应当以维护股东的合法权益、确保正常程 序和议事效率为原则，认真履行法定职责。股东会设立秘书处，负责股东会有关 程序方面事宜。 二、各股东（含股东代理人，下同）请按照本次股东会会议通知中规定的时 间和登记方法办理参会手续，详见公司刊登于上海证券交易所网站 （www.sse.com.cn）的《关于召开 2024 年年度股东会的通知》（公告编号：2025- 020）。为确认出席股东会的股东及其他出席者的参会资 ...

Group 1 - The core viewpoint of the news is that NuoVaxan's stock has shown a slight increase, with a closing price of 22.49 yuan, reflecting a 1.90% rise and a market capitalization of 8.945 billion yuan [1] - As of March 31, 2025, NuoVaxan has 8,397 shareholders, an increase of 671 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - NuoVaxan's main business focuses on the research and development of functional proteins and high molecular organic materials, with key products including biological reagents, diagnostic reagents, equipment, technical services, and consumables [1] Group 2 - In the latest quarterly report for Q1 2025, NuoVaxan reported a revenue of 285 million yuan, representing a year-on-year decrease of 5.50%, and a net profit of 1.9099 million yuan, down 63.39% year-on-year, with a gross profit margin of 69.40% [1] - The company's price-to-earnings (PE) ratio is significantly negative at -417.99 (TTM) and -494.37 (static), while the industry average PE is 48.90 (TTM) and 47.00 (static) [2] - The market valuation of NuoVaxan is 8.945 billion yuan, with a price-to-book ratio of 2.29, compared to the industry median of 2.40 [2]

Core Insights - The biopharmaceutical industry is a strategic emerging industry crucial for national economy and security, with a significant growth of 13.7% in pharmaceutical manufacturing in Nanjing during Q1 2025, driven by innovation and a vibrant ecosystem of high-tech enterprises [1][8]. Group 1: Innovation and Product Development - Jiangsu Aosai Kang Pharmaceutical Co., Ltd. launched its first class innovative drug, Liratinib tablets, approved for non-small cell lung cancer, marking it as the first innovative drug approved in the province this year [2]. - Nanjing Novozan Biotechnology Co., Ltd. plans to launch six new Alzheimer's disease testing kits, with four being the first of their kind in the country, enhancing early detection capabilities [2][3]. - The new Alzheimer's testing kits are expected to receive regulatory approval by Q3, further simplifying the testing process from cerebrospinal fluid to blood samples [3]. Group 2: Ecosystem and Collaboration - Nanjing has established a deep integration of "industry-university-research-medical" collaboration, positioning itself as a hub for biopharmaceutical innovation, with significant clinical trial and drug approval activity [4][6]. - The city has created a favorable environment for research and development, with over 200 innovation platforms supporting various stages of drug creation [7]. - A strategic cooperation agreement was signed to support biopharmaceutical research and development, with a commitment of 2 billion yuan in diversified capital investment [9][10]. Group 3: Market Growth and Future Plans - The biopharmaceutical industry in Nanjing is projected to generate over 210 billion yuan in revenue in 2024, reflecting a 5% growth, indicating simultaneous scale and quality improvements [8]. - Nanjing aims to enhance its innovation ecosystem by promoting the transformation of cutting-edge research into commercial products, while also attracting leading technology firms [10].

Investment Rating - The report indicates a cautious outlook for the pharmaceutical industry, with a focus on recovery in 2024 after a challenging 2023 due to anti-corruption measures [6][19]. Core Insights - The pharmaceutical industry is projected to see a decline in sales revenue and net profit for 2024 compared to 2023, with total sales revenue growth at -0.46%, net profit at -6.73%, and non-recurring net profit at -11.97% [2][13]. - The fastest-growing segments in Q4 2024 are expected to be CXO, medical devices, and pharmaceutical distribution, while in Q1 2025, the growth leaders will shift to CXO, pharmacies, and pharmaceutical distribution [22]. - The report highlights a significant slowdown in growth for traditional Chinese medicine and a mixed performance across various sectors, with some showing resilience and others facing challenges [5][24]. Summary by Sector Pharmaceutical Industry - In 2024, the total revenue growth for 405 pharmaceutical companies is projected at -0.46%, with net profit declining by 6.73% [2][13]. - Q1 2025 shows a continued decline in revenue and net profit, indicating ongoing challenges [13]. Traditional Chinese Medicine - For 62 listed companies in traditional Chinese medicine, revenue and net profit are expected to decline by -3.9% and -14.6% respectively in 2024, with further declines in Q1 2025 [24][32]. Chemical Preparations - The 96 chemical preparation companies are expected to see revenue growth of 1.2% and net profit growth of 15.7% in 2024, with a slight slowdown in Q1 2025 [2][5]. Research Services - The 16 research service companies are projected to experience a revenue increase of 6.56% in 2024, despite a significant drop in net profit [2][5]. Medical Services - The 11 medical service companies are expected to face revenue growth of 1.4% in 2024, with a notable recovery in Q1 2025 [2][5]. Medical Devices - The 97 medical device companies are projected to see a slight revenue increase of 1.16% in 2024, with a decline in net profit [2][5]. Biopharmaceuticals - The 54 biopharmaceutical companies are expected to see a revenue decline of -6.9% in 2024, with a significant drop in Q1 2025 [3][5]. CXO - The 22 CXO companies are projected to experience a revenue decline of -4.14% in 2024, but a recovery is anticipated in Q1 2025 with a revenue increase of 13.1% [3][5]. Raw Materials - The 50 raw material companies are expected to see a slight revenue increase of 2.48% in 2024, with a recovery trend starting in Q1 2025 [3][5]. Pharmacies - The 7 pharmacy companies are projected to see revenue growth of 4.9% in 2024, but face challenges in Q1 2025 [2][5]. Pharmaceutical Distribution - The 22 pharmaceutical distribution companies are expected to see a slight revenue increase of 0.27% in 2024, with ongoing challenges in Q1 2025 [2][5].

证券代码：688105 证券简称：诺唯赞 公告编号：2025-020 南京诺唯赞生物科技股份有限公司 关于召开2024年年度股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2024年年度股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 19 日至2025 年 5 月 19 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互 1 股东会召开日期：2025年5月19日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-019 南京诺唯赞生物科技股份有限公司 第二届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司(以下简称"公司")第二届监事会第十四 次会议（以下简称"会议"）于 2025 年 4 月 22 日以邮件的方式向全体监事发出 会议通知，并于 2025 年 4 月 28 日以通讯表决方式召开。本次会议由公司第二届 监事会主席张国洋先生主持，应出席监事 3 人，实际出席监事 3 人。本次会议的 通知、召开及审议程序符合《公司法》等有关法律法规及《公司章程》的规定。 会议审议通过如下议案： 审议通过《2025 年度第一季度报告》 监事会认为，公司 2025 年第一季度报告的编制和审议程序符合相关法律法 规及《公司章程》等内部规章制度的规定，内容与格式符合相关规定，真实、准 确、完整地反映了公司 2025 年第一季度的财务状况和经营成果等事项，不存在 任何虚假记载、误导性陈述或重大遗漏。在 2025 年第一季度报告编 ...

前十大流通股东累计持有： 30401.83万股，累计占流通股比： 76.44%，较上期变化： -65.12万股。 | 名称 | 持有数量(万股) | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 南京诺唯赞投资管理有限公司 | 16190.73 | 40.71 | 不变 | | 国寿成达(上海)健康产业股权投资中心(有限合伙) | 3095.80 | 7.78 | 不变 | | 杨奇 | 2187.29 | 5.50 | 不变 | | 曹林 | 2138.90 | 5.38 | 不变 | | 南京博英维创业投资合伙企业(有限合伙) | 1442.83 | 3.63 | 不变 | | 深圳旦恩先锋投资管理有限公司-深圳旦恩创业投资合伙 企业(有限合伙) | 1330.64 | 3.35 | -54.54 | | 南京唯赞创业投资合伙企业(有限合伙) | 1275.88 | 3.21 | 不变 | | 南京诺泰创业投资合伙企业(有限合伙) | 1174.25 | 2.95 | -10.58 | | 珠海广发信德敖东医药产业股权投资中心 ...

证券代码:688105 证券简称:诺唯赞 公告编号:2025-021 南京诺唯赞生物科技股份有限公司 关于召开2024年度暨2025年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"）已分别于 2025 年 4 月 10 日、2025 年 4 月 29 日发布公司 2024 年年度报告、公司 2025 年第一季度 报告，为便于广大投资者更全面深入地了解公司 2024 年度及 2025 年第一季度经 营成果、财务状况，公司计划于 2025 年 5 月 9 日上午 11：00-12：00 举行 2024 年度暨 2025 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度及 2025 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 1 会议召开时间 ...

科创投资研究 . 原【PE早餐】，升级聚焦为【科创投资研究】，宗旨为"关注科创动态，专注科创研究，聚焦科创项目，共享科创投资"。 作 者 | 科创投资研究 来源 | 科创投资研究 导 语：原股东套现离场，暴露出财务资本与产业资本在风险偏好上的根本分歧。 近日，青岛开发区投资建设集团（下称"开投集团"）通过股权划转及表决权委托，正式控股科创板上市公司瑞联新材（688550.SH）。 这场交易的特殊性在于：标的公司账面现金超10亿元，年营收近15亿元，净利润常年稳定在1.5亿-2亿元区间，但原控股股东却以7.5亿元对价出让控 制权。一时间，"原股东卖飞了"的质疑声四起。 表面看，这似乎是一场违背商业常识的交易：买方以低于标的净现金的价格拿下控制权，卖方主动放弃优质资产。 但穿透交易细节可以发现，从青岛国资的新材料产业布局，到原股东的资本困局，再到科创企业转型压力，多重因素交织下，这场交易的商业逻辑 远比账面数字复杂。 2025年3月20日，青岛开投集团通过协议受让及表决权委托，以总对价7.5亿元获得瑞联新材（688550.SH）31.58%的表决权，成为实际控制人。 以下文章来源于科创投资研究 ，作者深度的 这一 ...